CD8A and psoriasis: Dihydroartemisinin not only reduced acute skin lesions and recurrence of psoriasis in imiquimod (IMQ)-induced psoriasis-like mice, but also ameliorated psoriatic human skin lesions in humanized NSG mice receiving lesional skin from patients with psoriasis (11), mainly by diminishing CD8+ central memory T (TCM) and resident memory T (TRM) cells (11).